<DOC>
	<DOCNO>NCT01309698</DOCNO>
	<brief_summary>This study evaluate effect voglibose pharmacokinetics pharmacodynamics vildagliptin Japanese patient type 2 diabetes .</brief_summary>
	<brief_title>Drug Interaction Vildagliptin ( LAF237 ) With Voglibose Japanese Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Voglibose</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<criteria>Diabetic patient inadequately control diet therapy exercise therapy ( HbA1c range 6.5 10.0 % inclusive NGSP ) Fasting plasma glucose â‰¥ 270 mg/dL A history Type 1 diabetes secondary form diabetes Treatment antidiabetic agent include GLP1 analogue within 8 week insulin within 6 month prior screen Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drug interaction</keyword>
</DOC>